Free Trial
NASDAQ:SYBX

Synlogic (SYBX) Stock Price, News & Analysis

Synlogic logo
$1.16 +0.02 (+1.75%)
As of 05/2/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Synlogic Stock (NASDAQ:SYBX)

Key Stats

Today's Range
$1.07
$1.20
50-Day Range
$0.97
$1.40
52-Week Range
$0.90
$1.91
Volume
1,971 shs
Average Volume
19,234 shs
Market Capitalization
$13.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

Receive SYBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synlogic and its competitors with MarketBeat's FREE daily newsletter.

SYBX Stock News Headlines

Synlogic Reports Q3 2024 Financial Outcomes
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
Synlogic Reports Third Quarter 2024 Financial Results
Synlogic, Inc. (0A8U.L)
MIN.SG,0P0001I7V6,0 (MIN.SG)
See More Headlines

SYBX Stock Analysis - Frequently Asked Questions

Synlogic's stock was trading at $1.40 at the beginning of 2025. Since then, SYBX stock has decreased by 17.1% and is now trading at $1.16.
View the best growth stocks for 2025 here
.

Synlogic, Inc. (NASDAQ:SYBX) issued its earnings results on Thursday, March, 6th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.04.

Synlogic's stock reverse split before market open on Thursday, September 28th 2023. The 1-15 reverse split was announced on Thursday, September 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of SYBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Synlogic investors own include Reata Pharmaceuticals (RETA), Sangamo Therapeutics (SGMO), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE) and Exelixis (EXEL).

Company Calendar

Last Earnings
3/06/2025
Today
5/04/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SYBX
Employees
80
Year Founded
2013

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-57,280,000.00
Pretax Margin
-1,591.50%

Debt

Sales & Book Value

Annual Sales
$8,000.00
Price / Cash Flow
N/A
Book Value
$4.64 per share
Price / Book
0.25

Miscellaneous

Free Float
11,343,000
Market Cap
$13.57 million
Optionable
Optionable
Beta
0.56

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:SYBX) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners